Skip to NavigationSkip to content

Olumiant

Lilly & Incyte's Olumiant hits main goal in atopic dermatitis

Eli Lilly and Incyte have lifted the curtain on new Phase 3 data showing that their oral JAK inhibitor, showing that the candidate met its primary endpoint in the treatment of atopic dermatitis.

The data concerned Olumiant (baricitinib) in combination with topical corticosteroids (TCS) for the treatment of moderate to severe atopic dermatitis (AD) in adults who were inadequate responders, intolerant or had contraindication to treatment with cyclosporine.

New ICER report reveals most cost-effective rheumatoid arthritis therapies

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of three JAK inhibitors for treating rheumatoid arthritis (RA): AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib), and Eli Lilly’s Olumiant (baricitinib).

Head-to-head data revealed that Rinvoq demonstrated “statistically-significant but modestly higher rates of disease remission and improvement in other important outcomes” compared to AbbVie’s best-selling drug Humira; the report asserted that it could be assumed with “moderate certain

Lilly's Olumiant impresses in twin Phase 3 atopic dermatitis trials

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). The company and its partner Incyte announced that the drug had met its primary endpoint as a monotherapy in the treatment of adult patients with moderate to severe atopic dermatitis (AD).

Specifically, the pair revealed that a “statistically significant” proportion of patients treated with the therapy achieved clear or almost clear skin after 16 weeks compared to placebo, as measured according to the Investigator's Global Assessment for AD (IGA).

FDA greenlights Lilly's Olumiant in rheumatoid arthritis, with major caveats

Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to one or more tumour necrosis factor (TNF) inhibitor therapies.

However, the approval in the US only covered the lower dosage of 2mg after an FDA advisory panel voted in April to block the 4mg dose over safety concerns – a stark difference from the decision in over 40 countries to authorise the sale of both a high and low dosage.

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches